This article is more than 5 years old. Information may no longer be current.
ISTO Technologies appoints new CEO, board of director member
Click Here to Manage Email Alerts
ISTO Technologies Inc. has named George W. Dunbar, Jr. as president and chief executive officer and the company appointed James McGorry to its board of directors.
With over 25 years’ experience in the field of life sciences, Dunbar joins ISTO from Arboretum Ventures, where he evaluated investment opportunities in diagnostics, life science tools and medical devices. During this time he also founded a management consulting practice, The Dunbar Group, to mentor and guide early stage health care management teams on capital efficiency, creating market value and execution of timely liquidity events for investors. Prior to joining Arboretum, Dunbar was president, chief executive officer and later chairman of Aastrom Biosciences, according to an ISTO press release.
Previously, Dunbar was chief executive officer of numerous public and venture-backed life sciences companies, worked with several national venture capital investment firms and held senior positions in licensing, business development and marketing with the Ares-Serono Group and Amersham International. Dunbar is director of Capricor Therapeutics, Diagnovus and several of Arboretum Venture’s portfolio companies.
“George Dunbar’s proven leadership and broad experience, along with his recognized skill as a strategic change agent, will help build value for ISTO and drive wider recognition of our cell-based cartilage products, as well as other products in clinical development that are soon to be introduced,” Mitchell Seyedin, PhD, previous president and chief executive officer of ISTO, stated. “His entrepreneurial approach to building health care and bioscience companies, as well as his emphasis on individual and team accountability, makes him superbly suited to this role.” McGorry is executive vice president and general manager of the Translational Oncology Solutions for Champions Oncology. He was previously executive vice president of Accellent and spent 12 years with Genzyme, ultimately as senior vice president of oncology and transplant, responsible for establishing and executing the commercial development, product general management and global expansion of Genzyme’s oncology franchise in 90 countries. McGorry has held previous positions with Baxter Healthcare and American Hospital Supply and serves on the board of directors of Harvard Apparatus Regenerative Medicine.